Monte Rosa J J Supply Deal Refocuses MRT 2359 Prostate Cancer Story [Yahoo! Finance]
Monte Rosa Therapeutics, Inc. (GLUE)
Company Research
Source: Yahoo! Finance
Monte Rosa Therapeutics (NasdaqGS:GLUE) announced a new supply agreement with Johnson & Johnson to evaluate MRT-2359 with ERLEADA in metastatic castration resistant prostate cancer. The company is initiating a Phase 2 trial of the MRT-2359 plus ERLEADA combination in this setting. Additional positive clinical data for MRT-2359 in advanced prostate cancer were presented at ASCO GU 2026. Monte Rosa Therapeutics enters this news cycle with its shares at $15.63 and a 1 year return of 169.5%. Over shorter periods, the stock has seen a 2.4% decline over the past week and a 14.5% decline over the past month, while the year to date return stands at 2.1%, giving investors a mix of sharp longer term appreciation and recent volatility. The new supply agreement with Johnson & Johnson, the planned Phase 2 trial, and the latest ASCO GU 2026 data all add fresh information about MRT-2359 and Monte Rosa's clinical plans. For investors following NasdaqGS:GLUE, these developments may influence
Show less
Read more
Impact Snapshot
Event Time:
GLUE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GLUE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GLUE alerts
High impacting Monte Rosa Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
GLUE
News
- Monte Rosa Therapeutics (GLUE) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=GLUE&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> fromMarketBeat
- Monte Rosa Therapeutics (GLUE) had its price target lowered by Guggenheim from $34.00 to $30.00. They now have a "buy" rating on the stock.MarketBeat
- Monte Rosa Therapeutics (GLUE) had its price target lowered by Wells Fargo & Company from $30.00 to $29.00. They now have an "overweight" rating on the stock.MarketBeat
- Monte Rosa Therapeutics (GLUE) Reports Q4 Loss, Misses Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Monte Rosa Therapeutics touts molecular glue pipeline, tees up GFORCE updates and Phase II plans [Yahoo! Finance]Yahoo! Finance
GLUE
Sec Filings
- 3/19/26 - Form SCHEDULE
- 3/18/26 - Form S-8
- 3/17/26 - Form 10-K
- GLUE's page on the SEC website